This Ontario listing comes two months after Canada's Drug Agency (formerly CADTH) issued a reimbursement recommendation for VRAYLAR, and just days after AbbVie successfully reached an agreement ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

AbbVie cautions that these forward-looking statements ... achieving in-play patient leadership across all lines of therapy in the U.S, Japan and Canada. Skyrizi’s U.S. in-play patient share ...

The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...

The CEO of Hungarian pharmaceutical company Richter reiterated 2024 guidance on Tuesday after it reported higher ...

For more information about AbbVie, please visit us at www.abbvie.ca. Follow AbbVie Canada on Twitter, on Instagram or find us on LinkedIn. 1 Mental Health Commission of Canada. The Aspiring Workforce: ...

AbbVie is currently addressing serious health ... 30% from Western Europe, Canada, Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the third quarter ended September 30, 2024.